Immunohistochemical expression of cyclin D1 in invasive breast carcinoma and its correlation with clinicopathological parameters. 2020

Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
Department of Pathology, Smt. Kashibai Navale Medical College and General Hospital, Pune, Maharashtra, India.

BACKGROUND Breast cancer (BC) is the most common cancer and leading cause of death in women. OBJECTIVE This study was conducted to study the cyclin D1 expression in BC and its correlation with other clinicopathological parameters such as tumor size, histological grade, lymph node status, estrogen receptor (ER), progesterone receptor (PR), HER2/neu, and Ki67 status. METHODS Fifty cases of BC diagnosed between 2015 and 2018 were included in the study. A technique of manual tissue microarray was employed for the analysis of expression of immunohistochemical (IHC) markers such as cyclin D1, ER, PR, HER2/neu, and Ki67 in all cases. Results were subjected to statistical analysis. RESULTS Cyclin D1 positivity was seen in 64% cases of BC cases of which 8% were triple negative BC (TNBC) molecular subtype. Cyclin D1 expression was statistically significantly associated with ER and PR positivity. Maximum cases showing cyclin D1 expression showed negative HER2/neu expression, Ki67 immunopositivity, absent lymphovascular invasion and were of lower grade and stage. 32% cases were TNBC. Cyclin D1 was found positive in 25% TNBC cases. Negative Cyclin D1 expression was seen in TNBC cases of higher grade and higher stage with positive lymph node status, presence of lymphovascular invasion and Ki67 positivity. CONCLUSIONS Cyclin D1 can be potentially used as a prognostic marker and if included in routine IHC workup of BC cases can aid in appropriate patient management with the advent of new targeted therapy that blocks the cyclin D-CDK4/6 axis.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D046888 Tissue Array Analysis The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips. Cell Array Analysis,Cell Microarray Analysis,Tissue Microarray Analysis,Analyses, Cell Array,Analyses, Cell Microarray,Analyses, Tissue Array,Analyses, Tissue Microarray,Analysis, Cell Array,Analysis, Cell Microarray,Analysis, Tissue Array,Analysis, Tissue Microarray,Array Analyses, Cell,Array Analyses, Tissue,Array Analysis, Cell,Array Analysis, Tissue,Cell Array Analyses,Cell Microarray Analyses,Microarray Analyses, Cell,Microarray Analyses, Tissue,Microarray Analysis, Cell,Microarray Analysis, Tissue,Tissue Array Analyses,Tissue Microarray Analyses

Related Publications

Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
January 2019, Nigerian medical journal : journal of the Nigeria Medical Association,
Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
February 2006, Bulletin du cancer,
Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
January 2014, Journal of cancer research and therapeutics,
Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
January 2015, South Asian journal of cancer,
Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
April 2022, Archives of Iranian medicine,
Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
June 2019, African health sciences,
Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
January 2019, South Asian journal of cancer,
Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
January 2017, The journal of breast health,
Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
January 2001, Pathology, research and practice,
Pranoti Vitthalrao Lengare, and Siddhi Gaurish Sinai Khandeparkar, and Avinash R Joshi, and Bageshri P Gogate, and Smita Ganeshrao Solanke, and Sujit Hanumant Gore
February 1998, Molecular pathology : MP,
Copied contents to your clipboard!